case_images: PMC3872090_01
case_images: Case 1: pretreatment photos.
case_images: ccid-7-011Fig1.jpg
case_images: PMC3872090_01_ccid-7-011Fig1.jpg
case_images: f1-ccid-7-011
case_images: The patient experienced almost no response to the first treatment (Figures 1 and 2).
case_images: Case 1: 2 weeks posttreatment photos.
case_images: ccid-7-011Fig2.jpg
case_images: PMC3872090_01_ccid-7-011Fig2.jpg
case_images: f2-ccid-7-011
case_images: The patient experienced almost no response to the first treatment (Figures 1 and 2).
case_images: PMC3872090_02
case_images: Case 2: pretreatment photos.
case_images: ccid-7-011Fig3.jpg
case_images: PMC3872090_02_ccid-7-011Fig3.jpg
case_images: f3-ccid-7-011
case_images: In May 2010, the woman received further injections with abobotulinumtoxinA (Dysport ) in the glabella, frontalis, orbicularis oculi, and platysmal bands (Table 2), but reported that the treatment was not working as well as it had been (Figures 3 and 4).
case_images: Case 2: 2 weeks posttreatment photo.
case_images: ccid-7-011Fig4.jpg
case_images: PMC3872090_02_ccid-7-011Fig4.jpg
case_images: f4-ccid-7-011
case_images: In May 2010, the woman received further injections with abobotulinumtoxinA (Dysport ) in the glabella, frontalis, orbicularis oculi, and platysmal bands (Table 2), but reported that the treatment was not working as well as it had been (Figures 3 and 4).
case_images: PMC3872090_03
case_images: PMC3872090_04
case_images: PMC3872090_05